Диссертация (1154755), страница 14
Текст из файла (страница 14)
2012; 11(4): 70-78.13.Рачинская ЗВ. Оценка эффективности и переносимостилечения аторвастатином (тулипом) у больных ишемической болезньюсердца. Сибирский медицинский журнал. 2007; 6: 91-92.14.Сусеков А В, Зубарева МЮ, Деев А Д., и др. Основныерезультаты МосковскогоИсследования по Статинам (Moscow StatinSurvey, MSS). Сердце. 2006; 6: 324-328.15.Сусеков А.В. Холестерин липопротеинов низкой плотности(ХС-ЛНП) и реминантный холестерин неЛВП: нужна ли рокировка дляоценки сердечно-сосудистого риска? Медицинский совет. 2013; 9: 50–55.10016.Сусеков АВ, Блохин АБ, Лугинова ЗГ, и др. Статины впрофилактике ишемического инсульта. Рациональная фармакотерапия вкардиологии. 2013; 9(4): 409-416.17.России:Шальнова СА, Деев АД. Ишемическая болезнь сердца враспространенностьилечение(поданнымклинико-эпидемиологических исследований). Тер арх.
2011;1:7-12.18.“Эвиденс – Клинико-фармакологические исследования”.Инструкция по обработке данных, полученных с помощью опросника SF36. http://therapy.irkutsk.ru/doc/sf36a.pdf19.Эрлих А.Д, Грацианский Н. А. от имени участниковрегистра РЕКОРД. Результаты шестимесячного наблюдения за больнымис острыми коронарными синдромами в Российском регистре РЕКОРД.Кардиология. 2011; 12: 11-16.20.Andersohn F: Adherence to statin therapy: the key to survival?Int J Clin Pract.
2010; 64: 843–847.21.Argalious M, Xu M, Sun Z, et al. Preoperative statin therapy isnot associated with a reduced incidence of postoperative acute kidney injuryafter cardiac surgery. Anesth Analg. 2010; 111: 324–330.22.Arnold SV, Kosiborod M, Tang F, et al. Patterns of StatinInitiation, Intensification, and Maximization Among Patients Hospitalized withan Acute Myocardial Infarction. Circulation. 2014; 129: 1303-1309.23.Baigent C, Keech A, Kearney PM et al. Efficacy and safety ofcholesterol-lowering treatment: Prospective meta-analysis of data from 90,056participants in 14 randomised trials of statins. Lancet. 2005; 366: 1267-1278.doi: 10.1016/S0140-6736(05)67394-1.24.Bernick C, Katz R, Smith NL, et al. Statins and cognitivefunction in the elderly. Neurology.
2005; 65(9): 1388-1394.25.Bettermann K, Arnold AM, Williamson J, et al. Statins, risk ofdementia, and cognitive function: secondary analysis of the ginkgo evaluationof memory study. J Stroke Cerebrovasc Dis 2011; 21(6): 436–44.10126.Beydoun MA, Beason-Held LL, Kitner-Triolo MH, et al.Statins and serum cholesterol’s associations with incident dementia and mildcognitive impairment. J Epidemiol Community Health 2011; 65(11): 949–57.27.Boekholdt SM, Hovingh GK, Mora S, et al.
Very low levels ofatherogenic lipoproteins and the risk for cardiovascular events: a meta-analysisof statin trials. J Am Coll Cardiol. 2014; 64:485-94.28.Brass LM, Alberts MJ, Sparks L. An assessment of statin safetyby neurologists. Am J Cardiol 2006; 97 (8A): 86С.9.29.Briel M, Studer M, Glass TR, et al. Effects of statins on strokeprevention in patients with and without coronary heart disease: a metaanalysisof randomized controlled trials.
Am J Med. 2004; 117: 596–606.30.Brunelli SM, Waikar SS, Bateman BT, et al. Preoperative statinuse and postoperative acute kidney injury. Am J Med. 2012; 125: 195-204, e3.31.Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin orAtorvastatin Evaluation and Infection Therapy–Thrombolysis in MyocardialInfarction 22 Investigator. Intensive versus moderate lipid lowering with statinsafter acute coronary syndromes. N Engl J Med. 2004; 350: 1495-1504.32.Carter AA, Gomes T, Camacho X,et al. Risk of incidentdiabetes among patients treated with statins: population based study.BMJ 2013; 346: f2610.33.Catapano AL, De Backer G, Wiklund O, et al.
ESC/EASGuidelines for the management of dyslipidaemias. Eur Heart J. Advance AccesspublishedAugust27,2016.doi:10.1093/eurheartj/ehw272(http://eurheartj.oxfordjournals.org/content/early/2016/08/26/eurheartj.ehw272).34.CholesterolTreatmentTrialists'(CTT)Collaborators.Emberson J, Keaney PM, Blackwell L, et al. Lack of Effect of Lowering LDLCholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 Peoplein 27 Randomised Trials of Statin Therapy. Plos One. 2012; 7: e29849.10235.CholesterolTreatmentTrialists'(CTT)Collaborators.Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDLcholesterol with statin therapy in people at low risk of vascular disease: metaanalysis of individual data from 27 randomised trials.
Lancet. 2012; 380: 581–590.Cholesterol Treatment Trialists’ (CTT) Collaboration. Baigent36.C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensivelowering of LDL cholesterol: a meta-analysis of data from 170,000 participantsin 26 randomised trials. Lancet. 2010; 376: 1670-81.37.De Lemos JA, Blazing MA, Wiviott SD, et al. Early intensivevs a delayed conservative simvastatin strategy in patients with acute coronarysyndromes: phase Z of the A to Z trial.
JAMA. 2004; 292: 1307-1316.38.De Vera MA, Bhole V, Burns LC, et al. Impact of statinadherence on cardiovascular disease and mortality outcomes: a systematicreview. Br J Clin Pharmacol. 2014; 78: 684–698.39.Deedwania P, Barter P, Carmena R et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease andmetabolic syndrome: analysis of the Treating to New Targets study. Lancet.2006; 368: 919-928.40.Dimitrova Y, Dunoyer-Geindre S, Reber G, et al. Effects ofstatins on adhesion molecule expression in endothelial cells. J Thromb Haemost2003; 1: 2290-2299.41.FDAexpandsadviceonstatinrisks(www.fda.gov/ForConsumers/ConsumersUpdates/ucm293330.html).42.Feldman H, Levy AR, Hsiung GY, et al.
A Canadian cohortstudy of cognitive impairment and related dementias (ACCORD): studymethods and baseline results. Neuroepidemiology. 2003; 22: 265–274.43.symptomsFeng L, Yap KB, Kua EH, et al. Statin use and depressiveinaprospectivestudyofcommunity-livingpersons. Pharmacoepidemiol. Drug Saf. 2010; 19: 942–948.older10344.Finegold JA, Manisty CH, Goldacre B, et al. What proportionof symptomatic side effects in patients taking statins are genuinely caused bythe drug? Systematic review of randomized placebo-controlled trials to aidindividual patient choice.
Eur J Prev Cardiol. 2014; 21(4): 464-474.45.Gaist D, Jeppesen U, Andersen M, et al. Statins and risk ofpolyneuropathy: a case.control study. Neurology 2002; 58: 1333.7.46.Gehlbach P1, Li T, Hatef E. Statins for age-related maculardegeneration. Cochrane Database Syst Rev. 2012; 3: CD006927.47.Gitt AK, Drexel H, Feely J, et al. Persistent lipid abnormalitiesin statin-treated patients and predictors of LDL-cholesterol goal achievement inclinical practice in Europe and Canada.
Eur J Prevent Cardiol. 2012; 19: 221230.48.Golomb BA, Evans MA, Dimsdale JE, et al. Effects of statinson energy and fatigue with exertion: results from a randomized controlled trial.Arch Intern Med 2012; 172: 1180–1182.49.Grundy SM; Expert Dyslipidemia Panel. An InternationalAtherosclerosis Society Position Paper: global recommendations for themanagement of dyslipidemia. J Clin Lipidol.
2013; 7(6): 561-565.50.Hachinski V, Iadecola C, Petersen RC, et al. National Instituteof Neurological Disorders and Stroke-Canadian Stroke Network vascularcognitive impairment harmonization standards. Stroke. 2006; 37: 2220–2241.51.Hansen KE, Hildebrand JP, Ferguson EE, et al. Outcomes in 45patients with statin-associated myopathy. Arch Intern Med. 2005;165(22):2671-2676.52.Hippisley-Cox J, Coupland C. The effect of statins on mortalityin patients with ischaemic heart disease: population-based cohort study withcase control analysis.
Heart. 2006; 92: 752-758.53.Hopewell JC, Parish S, Off er A, et al. Impact of commongenetic variation on response to simvastatin therapy among 18 705 participantsin the Heart Protection Study. Eur Heart J. 2013; 34: 982–92.10454.Chyu KY, Shah PK. HDL/ApoA-1 infusion and ApoA-1 genetherapy in atherosclerosis. Front Pharmacol. 2015; 6: 187.55.http://www.mocatest.org/wp-content/uploads/2015/tests-instructions/MoCA-Instructions-Russian_2010.pdf56.Jameson K, Amber V, D’Oca K, et al.
Impact of lipid-loweringtherapy on the prevalence of dyslipidaemia in patients at high-risk ofcardiovascular events in UK primary care – a retrospective database study. Int JClin Pract. 2013; 67:1228-37.57.Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for theearly management of patients with acute ischemic stroke: a guideline forhealthcare professionals from the American Heart Association/American StrokeAssociation. Stroke.
2013; 44(3): 870-947.58.Jukema JW, Cannon CP, de Craen AJ, et al. The controversiesof statin therapy: weighing the evidence. J Am Coll Cardiol. 2012; 60(10): 87581.59.Kearney PM, Blackwell L, Collins R et al. Efficacy ofcholesterol-lowering therapy in 18,686 people with diabetes in 14 randomisedtrials of statins: a meta-analysis. Lancet. 2008; 371: 117-125. doi:10.1016/S0140-6736(08)60104-X.60.Kim MC, Cho JY, Jeong HC, et al. Impact of postdischargestatin withdrawal on long-term outcomes in patients with acute myocardialinfarction. Am J Cardiol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
